{"id":"W3119851230","doi":"10.1016/j.cgh.2021.01.006","title":"Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor","year":2021,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Western University; Mount Sinai Hospital","funders":"Samsung; National Institutes of Health; Ferring Pharmaceuticals; Shire; Crohn's and Colitis Foundation; American Gastroenterological Association; Leona M. and Harry B. Helmsley Charitable Trust; Israel National Road Safety Authority; AbbVie; Kenneth Rainin Foundation; U.S. Department of Defense; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim; Janssen Pharmaceuticals; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; School of Public Health, University of California Berkeley; Pfizer; Roche","keywords":"Medicine; Antibody; Tumor necrosis factor alpha; Drug; Tumor necrosis factor α; Necrosis; Immunology; Pathology; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002882179,0.0002144434,0.000447828,0.0009168368,0.0002829754,0.0006884768,0.0001487427,0.0003590545,0.01044919],"category_scores_gemma":[0.002061457,0.000100299,0.0006014921,0.001690773,0.0001597085,0.000457575,0.0002185678,0.0005799696,0.001547677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001613642,"about_ca_system_score_gemma":0.0002560831,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001276167,"about_ca_topic_score_gemma":0.001819679,"domain_scores_codex":[0.9997275,0.00005337934,0.00004803432,0.00005211357,0.00007749201,0.0000414754],"domain_scores_gemma":[0.9984785,0.0003016492,0.0009522791,0.00004032586,0.000106314,0.0001210103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008849217,0.000164101,0.9351818,0.0006564797,0.0002709035,0.001042444,0.00009164395,0.00006763629,0.001973543,0.0001928323,0.0043255,0.05514814],"study_design_scores_gemma":[0.00005880281,0.0002623606,0.9805439,0.0002665699,0.0003499137,0.007268207,0.0002140804,0.0001457452,0.0005127334,0.0003315827,0.01002711,0.00001903888],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9586113,0.02158896,0.001143044,0.001674766,0.0002333876,0.00008015594,0.004256124,0.00005767632,0.01235462],"genre_scores_gemma":[0.9852535,0.006265877,0.001059005,0.0008238591,0.0002359174,0.00004196153,0.00282443,0.0000161377,0.003479237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01044919,"threshold_uncertainty_score":0.03495604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02581687621056559,"score_gpt":0.2927787168194055,"score_spread":0.2669618406088399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}